Top Markets
#1 Black Phoenix Black Phoenix +166.14%
#2 Islamic Coin Islamic Coin +158.06%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +32.85%
#5 Cryptopia Cryptopia +20.92%
#6 Quantum Resistant Ledger Quantum Resistant Ledger +19.43%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.49%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +16.82%
#9 Test Test +13.54%
#10 Palladium Network Palladium Network +11.40%
Coin of the day
Black Phoenix Black Phoenix
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Wuhan General Group (China), Inc. Wuhan General Group (China), Inc.

Wuhan General Group (China), Inc.

WUHN
Clasificación en acciones #41554
Wuhan General Group (China), Inc. is a nutraceutical biotechnology company,... Wuhan General Group (China), Inc. is a nutraceutical biotechnology company, which engages in the development of alternative plant-based cannabinoids and psilocybin medical research that commercializes a range of cannabidiol and mushrooms-based products under the Dr. AnnaRx, Medspresso and Handcrafted Delights brands. The firm is also engages in research and development of indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer's and Parkinson's. The company was founded by Xu Jie and Jeff Robinson on July 19, 1988 and is headquartered in Cape Town, South Africa.
Precio por acción
$0.0003
Última sincronización: 2026-08-11
Capitalización bursátil
$16.55K
Cambio (1 día)
0.00%
Cambio (1 año)
200.00%
País
ZA
Comercio Wuhan General Group (China), Inc. (WUHN)

Categoría

Healthcare
Ingresos de Wuhan General Group (China), Inc. (WUHN)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Wuhan General Group (China), Inc., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Wuhan General Group (China), Inc. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US